Skip to content

Cannabis: all studies

Page 116 of 287: studies 1,151 to 1,160 of 2,868, newest first. Back to the cannabis overview

Research

Cannabis psychosis, gender matters

European Psychiatry March 1, 2016 I. Hamilton, P. Galdas, H. Essex

IntroductionDespite recent findings pointing toward cannabis psychosis as one area where gender differences may exist, there has been a widespread lack of attention paid to gender as a determinant of health in both psychiatric services and within the field of addiction.ObjectivesTo explore gender differences in treatment presentations for people with cannabis psychosis.AimsTo use national data...

Abnormal medial prefrontal cortex activity in heavy cannabis users during conscious emotional evaluation.

Psychopharmacology March 1, 2016 Michael J Wesley, Joshua A Lile, Colleen Hanlon et al.

Long-term heavy cannabis users (cannabis users) who are not acutely intoxicated have diminished subconscious neural responsiveness to affective stimuli. This study sought to determine if abnormal processing extends to the conscious evaluation of emotional stimuli. Functional magnetic resonance imaging (fMRI) was used to examine brain activity as cannabis users (N = 16) and non-cannabis-using...

Mismatch Negativity and P50 Sensory Gating in Abstinent Former Cannabis Users

Journal of Neural Transplantation and Plasticity February 25, 2016 Samantha J Broyd, L. Greenwood, Hendrika H Van Hell et al.

Prolonged heavy exposure to cannabis is associated with impaired cognition and brain functional and structural alterations. We recently reported attenuated mismatch negativity (MMN) and altered P50 sensory gating in chronic cannabis users. This study investigated the extent of brain functional recovery (indexed by MMN and P50) in chronic users after cessation of use. Eighteen ex-users (median...

AKT1 genotype moderates the acute psychotomimetic effects of naturalistically smoked cannabis in young cannabis smokers.

Translational Psychiatry February 16, 2016 C J A Morgan, Tom P. Freeman, J Powell et al.

Smoking cannabis daily doubles an individual's risk of developing a psychotic disorder, yet indicators of specific vulnerability have proved largely elusive. Genetic variation is one potential risk modifier. Single-nucleotide polymorphisms in the AKT1 and catechol-O-methyltransferase (COMT) genes have been implicated in the interaction between cannabis, psychosis and cognition, but no studies...

Cannabis and Psychosis: a Critical Overview of the Relationship.

Current Psychiatry Reports February 1, 2016 Charles Ksir, Carl L. Hart

Interest in the relationship between cannabis use and psychosis has increased dramatically in recent years, in part because of concerns related to the growing availability of cannabis and potential risks to health and human functioning. There now exists a plethora of scientific articles addressing this issue, but few provide a clear verdict about the causal nature of the cannabis-psychosis...

Comparisons of Δ9-Tetrahydrocannabinol and Anandamide on a Battery of Cognition-Related Behavior in Nonhuman Primates.

Journal of Pharmacology and Experimental Therapeutics January 29, 2016 Brian D Kangas, Michael Z. Leonard, Vidyanand G Shukla et al.

The primary psychoactive ingredient of marijuana, Δ(9)-tetrahydrocannabinol (Δ(9)-THC), has medicinal value but also produces unwanted deleterious effects on cognitive function, promoting the search for improved cannabinergic therapeutics. The present studies used a battery of touchscreen procedures in squirrel monkeys to compare the effects of different types of cannabinergic drugs on several...

A Case of Butane Hash Oil (Marijuana Wax)–Induced Psychosis

Substance Abuse January 28, 2016 Corey J. Keller, Evan C. Chen, Kimberly L. Brodsky et al. 27 citations

BACKGROUND: Marijuana is one of the most widely used controlled substances in the United States. Despite extensive research on smoked marijuana, little is known regarding the potential psychotropic effects of marijuana "wax," a high-potency form of marijuana that is gaining in popularity. CASE: The authors present a case of "Mr. B," a 34-year-old veteran who presented with profound psychosis in...

Brain reactivity to alcohol and cannabis marketing during sobriety and intoxication

Addiction Biology January 14, 2016 Elizabeth B. de Sousa Fernandes Perna, Eef Lien Theunissen, Kim P. C. Kuypers et al. 24 citations

Drugs of abuse stimulate striatal dopamine release and activate reward pathways. This study examined the impact of alcohol and cannabis marketing on the reward circuit in alcohol and cannabis users while sober and intoxicated. It was predicted that alcohol and cannabis marketing would increase striatal activation when sober and that reward sensitivity would be less during alcohol and cannabis...

Hippocampal harms, protection and recovery following regular cannabis use.

Translational Psychiatry January 12, 2016 Murat Yücel, Valentina Lorenzetti, Chao Suo et al.

Shifting policies towards legalisation of cannabis for therapeutic and recreational use raise significant ethical issues for health-care providers seeking evidence-based recommendations. We investigated whether heavy cannabis use is associated with persistent harms to the hippocampus, if exposure to cannabidiol offers protection, and whether recovery occurs with abstinence. To do this, we...

Disruption of hippocampal synaptic transmission and long‐term potentiation by psychoactive synthetic cannabinoid ‘Spice’ compounds: comparison with Δ9‐tetrahydrocannabinol

Addiction Biology January 5, 2016 Alexander F. Hoffman, Matthew D. Lycas, Jakub Kaczmarzyk et al. 39 citations

Abstract There has been a marked increase in the availability of synthetic drugs designed to mimic the effects of marijuana. These cannabimimetic drugs, sold illicitly as ‘Spice’ and related products, are associated with serious medical complications in some users. In vitro studies suggest that synthetic cannabinoids in these preparations are potent agonists at central cannabinoid CB1 receptors...

DOI: 10.1111/adb.12334 (opens in new tab) Synthetic cannabinoids Am251 Cannabinoid receptor Long-term potentiation +6